"Wouldn’t be a day if I didn’t talk about GLP-1s” laughs Kasey Raetz, Pharm.D.

Like executives at nearly every pharmacy benefit manager (PBM) and payer, Raetz was seeing tsunami-like trends in prescriptions of the now-famous glucagon-like peptide 1 (GLP-1) drugs, which include Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss and the same drug marketed under different names for diabetes but used off-label for weight loss.

“I’ve never seen a category with so much demand,” Raetz continues. “And every person in America, whether they’re in the industry or not, can name these drugs, which is just incredible. We just have never seen this before.”

Raetz, who sports a mouthful of a title, vice president of product and pharma contracting and strategy at Express Scripts, and her tea

See Full Page